{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"condition":["Microsatellite Stable Advanced Metastatic Colorectal Cancer"],"disease":["Microsatellite Stable Advanced Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/105704"],"location":["China"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Study of EBRT Combined with Sintilimab+Furoquentinib in the Treatment of Microsatellite Stable Advanced Metastatic Colorectal Cancer","description":"Interventions: Test group :receiving EBRT plus Sintilimab+Furoquentinib triple therapy\nPrimary outcome(s): Objective Response Rate\nStudy Design: Single arm","dates":{"creation":"2023-08-15"},"accession":"105704","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2300074637"]}}